Does Ozempic Contain Semaglutide — and Does That Make It a Weight-Loss Medicine?

Step 1: Understand what semaglutide actually is

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone called glucagon-like peptide-1, which the body releases after eating. By activating GLP-1 receptors, semaglutide slows how quickly food leaves the stomach, reduces hunger signals sent to the brain, and helps regulate blood sugar. Those effects are useful both in type 2 diabetes (where blood-sugar control matters) and in weight management (where reduced appetite leads to a sustained calorie deficit over time).

The molecule itself does not change between products. What changes is the dose, the brand name, the approved indication, and the regulatory context in which it is prescribed. The NHS semaglutide medicines page covers both the diabetes and weight-loss presentations clearly, and is a useful reference if you want the patient-level overview.

One more form worth knowing about: oral semaglutide. Rybelsus is a daily tablet version licensed for type 2 diabetes. A different oral formulation, Wegovy tablets, received MHRA approval for weight management in June 2026, the first oral GLP-1 medicine licensed for that purpose in the UK. Same ingredient, four distinct licensed products, each with its own approved use.

Step 2: See why the licence difference is not just a technicality

Ozempic's UK licence, granted and maintained by the MHRA, specifies type 2 diabetes as the approved indication. That is the clinical context in which its dosing schedule, trial evidence and prescribing guidance were developed. The MHRA has stated publicly that GLP-1 medicines are not assessed for quick or cosmetic weight loss, and the question of whether Ozempic can be used for weight loss in the UK has a genuinely complicated answer that comes down to prescriber judgement, patient circumstance and the clinical evidence available.

Wegovy was approved on a separate evidence base, most prominently the STEP 1 trial, published in the New England Journal of Medicine, which showed an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, in adults with obesity and without diabetes. That evidence package is what gave Novo Nordisk its weight-management licence for Wegovy. It is also what NICE assessed when it recommended semaglutide (as Wegovy) for weight management in TA875.

Clinically, prescribing the wrong product for the wrong indication is not simply a paperwork problem. The dose schedule is different, the monitoring framework is different, and the criteria for when to stop are different. A prescriber who supplies Ozempic to a patient without diabetes, specifically for weight loss, is working well outside the product's authorised use.

Step 3: Know which semaglutide medicine is actually licensed for weight loss in the UK

Wegovy injection is the main licensed option. Its weekly dosing runs from 0.25 mg at the start, titrated gradually by a prescriber through 0.5 mg, 1.0 mg and 1.7 mg, up to the 2.4 mg maintenance dose. In April 2026 the MHRA approved a dedicated 7.2 mg single-dose pen (the highest available weekly dose) for adults with a BMI of 30 or above, following trial data reporting around 20.7% average weight loss over 72 weeks.

Wegovy tablets arrived in June 2026, providing an injection-free route for people who prefer it. The titration schedule for the tablet is different: it starts at 1.5 mg daily and steps up through 4 mg and 9 mg to the 25 mg maintenance dose, with at least a month at each level.

If you are weighing up the options, the full picture of how Wegovy works, who it suits and what to expect is worth reading alongside this page. And if the cost of private treatment is part of your thinking, a practical breakdown of what Wegovy actually costs through a regulated UK pharmacy sets honest expectations before you consult.

What about the relationship between Ozempic and Wegovy more broadly?

A question our prescribers field fairly regularly is whether Ozempic and Wegovy are interchangeable, or whether one is simply a rebrand of the other. They are not interchangeable, and it is not a rebrand. They share an active ingredient and a manufacturer. Beyond that, they are different licensed medicines with different dosing presentations, different approved patient populations, and different NICE recommendations.

The comparison between Wegovy and Ozempic goes into that distinction in more depth, including what it means in practice when a patient has been using Ozempic off-label and wants to transition. If you are curious about the dosing schedule in more clinical detail, the semaglutide dosing page covers both timelines side by side.

For anyone researching semaglutide more broadly (its mechanism, its trial history, how it fits into the UK regulatory landscape) the semaglutide overview pulls that together in one place. And for a focused explanation of exactly how Ozempic and semaglutide relate, this page answers that question directly.

One practical note: when Wegovy is dispensed through a regulated UK pharmacy, what arrives is a discreet plain box, no branding visible on the outside, with DPD tracking on your phone so you know exactly when to be home. That logistics detail matters because these pens need refrigeration when they arrive. It is worth making space in your fridge before delivery day.

Both Mounjaro and Wegovy are prescription-only medicines. If you have read enough to know you want a clinical conversation, our prescribers are available seven days a week. Speak to our prescribers to start your free consultation, same-day clinical review, no waiting list.